New drug combo shows promise for bladder cancer patients
NCT ID NCT04386746
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder for people with early-stage bladder cancer who had not received standard BCG therapy. The goal was to see if this treatment could prevent the cancer from coming back. 27 participants were enrolled, and the study is now active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States